

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
JURY VERDICT IN U.S. PATENT INFRINGEMENT LITIGATION

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest updates in respect of the intellectual property protection efforts of the Group.

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders and potential investors of the Company that a jury in the United States District Court for the District of Delaware (the “**Court**”) has returned a verdict in favor of Harbour Antibodies BV (together with other related parties, “**Harbour Antibodies**”), a member of the Group, in the patent infringement lawsuit originally filed in 2021 against Amgen Inc. and Teneobio, Inc., an Amgen subsidiary (together, “**Amgen**”) (the “**Litigation**”). The Litigation relates to certain patents protecting the Group’s antibody discovery platform, a groundbreaking invention made by Professor Frank Grosveld, a founder of Harbour Antibodies (each a “**Grosveld Patent**” and collectively, the “**Grosveld Patents**”).

Following a jury trial which commenced on 8 June 2026, the jury found, among other things, that (i) Amgen infringed Grosveld Patent, (ii) the infringement was willful, (iii) the Grosveld Patent is valid, and (iv) Harbour Antibodies is entitled to damages of US\$20,203,704, being the full amount requested at trial.

The finding of willful infringement provides a basis for Harbour Antibodies to petition the Court for enhanced damages, which may include up to treble damages. If such enhanced damages are granted in full, the award could increase to up to approximately US\$60.6 million. The Group will evaluate and, where appropriate, take further steps in respect of the verdict, potential enhanced damages and other proceedings relating to the Group’s broader patent portfolio.

The Company will make further announcement(s) on any material developments as and when appropriate in compliance with the Listing Rules.

Cautionary Statement: Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 15 June 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.